Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CSL Limited (AU:CSL)
:CSL
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
3.54Last Year’s EPS
2.86Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 11, 2025
|% Change Since: 0.75%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive sentiment, with strong financial performance led by CSL Behring and a promising outlook despite challenges in CSL Seqirus and specialty products due to external market conditions.Company Guidance
In the recent CSL Limited half-year financial results call for fiscal year 2025, the company reaffirmed its guidance for NPATA growth of 10% to 13%. Key metrics include a 5% increase in revenue to AUD 8.5 billion at constant currency, with NPATA and net profit after tax both up 5% and 7%, respectively. CSL Behring's revenue grew by 10%, driven by a 15% increase in the Ig franchise, while CSL Vifor recorded a 6% revenue growth. However, CSL Seqirus faced challenges with a 9% revenue decline due to reduced influenza vaccination rates in the US. The gross margin for CSL Behring improved by 170 basis points, aided by advancements in plasmapheresis technology. The company also plans to complete the rollout of new plasma collection technology by June. Overall, CSL expects revenue growth of 5% to 7% over the previous fiscal year at constant currency, with a projected NPATA range of AUD 3.2 to 3.3 billion.Strong Overall Financial Performance
Revenue was AUD 8.5 billion, up 5% at constant currency. NPATA was AUD 2.1 billion, up 5%, and net profit after tax was AUD 2 billion, up 7%.
CSL Behring's Robust Growth
CSL Behring delivered strong growth of 10%, driven by the Ig franchise, which grew 15%, and albumin with a 9% increase.
Innovative Product Rollouts
Implementation of Rika plasmapheresis machines and iNomi technology is advancing, with observed donor yield increases of around 10%.
Regulatory Approvals for ANDEMBRY
ANDEMBRY received regulatory approvals in Australia and the UK, a positive CHMP recommendation in the EU, and US FDA acceptance.
Positive Financial Outlook
CSL reaffirms guidance for fiscal year 2025, expecting NPATA growth of 10% to 13%.
---
AU:CSL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AU:CSL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 11, 2025 | AU$256.96 | AU$256.28 | -0.26% |
| Aug 12, 2024 | AU$306.69 | AU$292.64 | -4.58% |
| Feb 12, 2024 | AU$286.32 | AU$278.44 | -2.75% |
| Aug 14, 2023 | AU$257.52 | AU$267.12 | +3.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does CSL Limited (AU:CSL) report earnings?
CSL Limited (AU:CSL) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is CSL Limited (AU:CSL) earnings time?
CSL Limited (AU:CSL) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of CSL Limited stock?
The P/E ratio of CSL is N/A.
What is AU:CSL EPS forecast?
AU:CSL EPS forecast for the fiscal quarter 2025 (Q4) is 3.54.
---